-
1.发明公开公开(公告)号：US20230285321A1
公开(公告)日：2023-09-14
申请号：US18199523
申请日：2023-05-19
发明人： Gabriele Civiletto , Bernard Cuenoud , Jerome Feige , Philipp Gut
IPC分类号： A61K31/132 , A61K31/19 , A61K38/01 , A61K38/17
CPC分类号： A61K31/132 , A61K31/19 , A61K38/011 , A61K38/018 , A61K38/1709
摘要： Compositions and methods can use a combination of an autophagy inducer, such as spermidine, and high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing a combination of an autophagy inducer and high protein is administered to the individual in an amount effective to induce autophagy, for example in muscle. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials. The recipient of administration can be a critically ill patient, for example a patient in the Intensive Care Unit (ICU), and/or an ageing patient, for example an elderly individual or an individual with sarcopenia.
-
2.发明申请公开(公告)号：US20210228526A1
公开(公告)日：2021-07-29
申请号：US17258542
申请日：2019-07-09
IPC分类号： A61K31/23 , A23L33/115 , A23L33/17 , A23L33/125 , A23L33/00 , A23C9/152 , A61K47/42 , A61K9/00 , A61P3/00
摘要： A composition effective for treating or preventing a condition for which extended exposure to ketones is beneficial contains medium chain triglycerides (MCTs) and also contains proteins in a weight ratio of at least 0.1 g protein/1.0 g of the compound. Other aspects are directed to a method of extending blood exposure to ketones derived from oral absorption of a food product by an individual; a method of improving or maintaining at least one of neurologic health, cognitive function, or exercise performance; and a method of making the composition.
-
公开(公告)号：US20210267251A1
公开(公告)日：2021-09-02
申请号：US17254403
申请日：2019-05-24
发明人： Bernard Cuenoud , India C. Severin
IPC分类号： A23L33/00 , A23L33/125 , A61K31/121 , A61K31/455
摘要： A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione. The composition contains an effective amount of a combination of a Nicotinamide Adenine Dinucleotide (NAD+) precursor and at least one ketone or ketone precursor. The composition can be an enterally administered composition such as an orally administered food product or food supplement.
-
公开(公告)号：US20210121488A1
公开(公告)日：2021-04-29
申请号：US17254417
申请日：2019-05-24
IPC分类号： A61K31/706 , A61K31/19 , A61K31/121 , A61K9/00 , A23L33/00 , A23L33/125
摘要： A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione, in particular neurodegenerative disease, depression, anxiety, decreased/low motivation, impaired cognitive function, mild cognitive impairment. The composition contains an effective amount of a combination of a Nicotinamide Adenine Dinucleotide (NAD+) precursor and at least one ketone or ketone precursor. The composition can be an enterally administered composition such as an orally administered food product or food supplement.
-
公开(公告)号：US20220168256A1
公开(公告)日：2022-06-02
申请号：US17440021
申请日：2020-03-17
发明人： Bernard Cuenoud
摘要： A method increases production of ketones derived from oral consumption of medium chain triglycerides (MCT) by an individual. The method includes orally administering to the individual a composition containing the MCTs and then subsequently orally administering to the individual a meal at least about ten minutes after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The ketone production is increased relative to ketone production from oral administration of the MCTs and the meal at approximately the same time. The meal can be breakfast. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.
-
公开(公告)号：US20220184022A1
公开(公告)日：2022-06-16
申请号：US17595363
申请日：2020-05-20
发明人： Amaury Patin , Elizabeth Forbes-Blom , Pascal Steiner , Amy Pooler , Sarah Sonnay , Bernard Cuenoud
摘要： Use of a compound having the formula (1) (2) (3) or (4) or combinations thereof, for increasing blood ketone levels, and/or treating a disease treatable by increasing blood ketone levels, preferably wherein the disease is selected from the list consisting of: a brain energy deficiency condition, a neurological condition, migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, inherited metabolic disorders (such as glucose transporter type 1 deficiency syndrome and pyruvate dehydrogenase complex deficiency), depression, schizophrenia, epilepsy, narcolepsy, diabetes, obesity, non-alcoholic fatty liver disease and polycystic ovary syndrome, wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons.
-
公开(公告)号：US20220168257A1
公开(公告)日：2022-06-02
申请号：US17440246
申请日：2020-03-20
发明人： Bernard Cuenoud
摘要： A method reduces postprandial glucose from a meal. The method includes orally administering to an individual a composition containing medium chain triglycerides (MCT) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The postprandial glucose is reduced relative to postprandial glucose from (i) postprandial glucose from administration of an identically formulated composition containing MCTs at approximately the same time as the administration of the meal and (ii) postprandial glucose from administration of the meal without any MCTs within about one hour before or within about one hour afterward. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.
-
公开(公告)号：US20210085624A1
公开(公告)日：2021-03-25
申请号：US16954694
申请日：2018-12-19
发明人： Gabriele Civiletto , Bernard Cuenoud , Jerome Feige , Philipp Gut
IPC分类号： A61K31/132 , A61K38/17 , A61K38/01 , A61K31/19
摘要： Compositions and methods can use a combination of an autophagy inducer, such as spermidine, and high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing a combination of an autophagy inducer and high protein is administered to the individual in an amount effective to induce autophagy, for example in muscle. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials. The recipient of administration can be a critically ill patient, for example a patient in the Intensive Care Unit (ICU), and/or an ageing patient, for example an elderly individual or an individual with sarcopenia.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.015 秒)
